We are live on ! Find out more
VTAE

VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE

Delisted

VTAE was delisted on the 24th of October, 2016.

Back to rankings

34 hedge funds and large institutions have $120M invested in VITAE PHARMACEUTICALS INC COMMON STOCK in 2014 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

550% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 4

168% more capital invested

Capital invested by funds: $45M → $120M (+$75.5M)

127% more funds holding

Funds holding: 15 → 34 (+19)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
34
Holders Change
+19
Holders Change %
+126.67%
% of All Funds
0.91%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
26
Increased
3
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$15.9M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$1.87M
3
BI
BVF Inc
California
+$1.29M
4
EI
EAM Investors
California
+$1.15M
5
Northern Trust
Northern Trust
Illinois
+$883K

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.39M
2
WT
Wellcome Trust
United Kingdom
-$1.17M
3
Millennium Management
Millennium Management
New York
-$918K
4
Marshall Wace
Marshall Wace
United Kingdom
-$569K
5
Deutsche Bank
Deutsche Bank
Germany
-$477K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$43.5M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$28.3M +$15.9M +1,089,782 +178%
AIC
3
AWM Investment Company
New York
$13.7M +$12.1M +825,000 New
BI
4
BVF Inc
California
$12.5M +$1.29M +87,935 +13%
WT
5
Wellcome Trust
United Kingdom
$7.29M -$1.17M -79,886 -15%
EC
6
EcoR1 Capital
California
$3.44M +$3.03M +207,000 New
Vanguard Group
7
Vanguard Group
Pennsylvania
$2.13M +$1.87M +127,677 New
JP Morgan Chase
8
JP Morgan Chase
New York
$1.67M -$357K -24,400 -20%
EI
9
EAM Investors
California
$1.31M +$1.15M +78,477 New
Northern Trust
10
Northern Trust
Illinois
$1.01M +$883K +60,418 New
Geode Capital Management
11
Geode Capital Management
Massachusetts
$722K +$635K +43,409 New
ARTA
12
A.R.T. Advisors
New York
$684K +$602K +41,150 New
Goldman Sachs
13
Goldman Sachs
New York
$525K +$461K +31,561 New
State Street
14
State Street
Massachusetts
$496K +$436K +29,786 New
Citadel Advisors
15
Citadel Advisors
Florida
$451K +$396K +27,089 New
Morgan Stanley
16
Morgan Stanley
New York
$406K +$357K +24,408 New
Susquehanna International Group
17
Susquehanna International Group
Pennsylvania
$344K +$302K +20,687 New
Bank of New York Mellon
18
Bank of New York Mellon
New York
$318K +$279K +19,106 New
BIM
19
Bogle Investment Management
Massachusetts
$237K +$209K +14,285 New
Millennium Management
20
Millennium Management
New York
$230K -$918K -62,808 -82%
Charles Schwab
21
Charles Schwab
California
$228K +$200K +13,654 New
TCIM
22
TIAA CREF Investment Management
New York
$193K +$170K +11,627 New
VKH
23
Virtu KCG Holdings
New York
$188K +$165K +11,295 New
California State Teachers Retirement System (CalSTRS)
24
California State Teachers Retirement System (CalSTRS)
California
$173K +$152K +10,400 New
TA
25
Teachers Advisors
New York
$84K +$73.8K +5,047 New
1
2

VTAE Hedge Fund Activity: Q4 2014 in Review

34 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) for Q4 2014, worth a combined $120M — up 168% from $45M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new VTAE positions and 4 closed out — a net gain of 22 holders — while 3 added to existing stakes and 4 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $15.9M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.39M sold.

  • 34 institutional investors held VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) as of Q4 2014, up from 15 in Q3 2014.
  • Funds reported $120M of VITAE PHARMACEUTICALS INC COMMON STOCK stock for Q4 2014, up 168% quarter-over-quarter.
  • 26 funds opened new VITAE PHARMACEUTICALS INC COMMON STOCK positions in Q4 2014 and 4 closed out, a net change of +22 holders.
  • The largest VITAE PHARMACEUTICALS INC COMMON STOCK buyer in Q4 2014 was Fidelity Investments, an estimated $15.9M added.
  • The largest VITAE PHARMACEUTICALS INC COMMON STOCK seller in Q4 2014 was Alyeska Investment Group, an estimated $1.39M sold.

Based on aggregated 13F filings for Q4 2014.